OncoCyte
Insider trading & Transactions

Last updated:

Transaction Date Insider Security Shares Price per share Total value Source
Purchase
BROADWOOD PARTNERS, L.P. 10 percent owner
 Common Stock, no par value 2,000,000 $1.66 $3,320,000
Sale
LINEAGE CELL THERAPEUTICS, INC. other: Previous 10% Owner
 Common Stock, no par value 4,000,000 $1.66 $6,640,000
Sale
BIOTIME INC
Common Stock, no par value 2,250,000 $2 $4,500,000
Purchase
BROADWOOD PARTNERS, L.P. 10 percent owner
 Common Stock, no par value 0 $2 $0
Purchase
BROADWOOD PARTNERS, L.P. 10 percent owner
 Common Stock, no par value 533,333 N/A N/A
Purchase
HESTERBERG LYNDAL K. officer: CSO
 Common stock, no par value 874 N/A N/A
Purchase
LEVINE MITCHELL S officer: CFO
 Common stock, no par value 3,495 N/A N/A
Purchase
ANNETT WILLIAM director, officer: President an..
 Common stock, no par value 3,500 N/A N/A
Purchase
ANDREWS RONALD ASBURY director, officer: Chief Execut..
 Common stock, no par value 17,482 N/A N/A
Purchase
REDMOND CAVAN M. director
 Common stock, no par value 52,447 N/A N/A
Purchase
ARNO ANDREW director
 Common stock, no par value 52,447 N/A N/A
Purchase
LAST ANDREW J. director
 Common stock, no par value 6,993 N/A N/A
Purchase
BROADWOOD PARTNERS, L.P. 10 percent owner
 Common Stock, no par value 3,968,254 N/A N/A

Showing 100 to 113 of 113 results.

Insider trading

Monitoring trades made by the management members or major shareholders of companies may help create a sharper picture of what is happening inside the companies. Base your decisions on buys or sells of the people involved and do the right thing at the right time.

Who is insider?

Every director or senior officer, as well as any other entity or individual owning more than 10% of the company’s shares on the stock market, is called an insider. Such people or entities are allowed to buy/sell the company's shares under strictly controlled conditions. Key premise here is that none of them can make trades based on non-public information about the company.

Similar companies insider trading: